Ticker Details
Arbutus Biopharma Corporation Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.
IPO Date:	October 31, 2008
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.03B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.13 | 3.59%
Avg Daily Range (30 D):	$0.12 | 2.54%
Avg Daily Range (90 D):	$0.10 | 2.19%

Institutional Daily Volume
Avg Daily Volume:	1.23M
Avg Daily Volume (30 D):	1.75M
Avg Daily Volume (90 D):	1.75M

Trade Size
Avg Trade Size (Sh.):	205
Avg Trade Size (Sh.) (30 D):	150
Avg Trade Size (Sh.) (90 D):	142

Institutional Trades
Total Institutional Trades:	455
Avg Institutional Trade:	$1.6M
Avg Institutional Trade (30 D):	$1.63M
Avg Institutional Trade (90 D):	$1.79M
Avg Institutional Trade Volume:	.42M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.61M
Avg Closing Trade (30 D):	$1.32M
Avg Closing Trade (90 D):	$1.51M
Avg Closing Volume:	402K

News

Mar 5, 2026 @ 7:42 PM 9 Biotech Stocks Trading Far Below Fair Value With... Source: David Wagner

Mar 4, 2026 @ 1:14 PM Moderna's $950 Million Settlement Clears Legal Ove... Source: Vandana Singh

Feb 20, 2025 @ 8:22 AM Will Moderna Stock Drop to $25? 1 Wall Street Anal... Source: Eric Volkman

Jun 13, 2024 @ 9:12 AM Ultragenyx (RARE) Moves 7.8% Higher: Will This Str... Source: Zacks Equity Research

Jun 6, 2024 @ 3:15 PM Treatment with Arbutus’ Imdusiran and VTP-3... Source: Arbutus Biopharma Corporation

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$.79	$-.03	$.88
Diluted EPS	$.79	$-.03	$.87
Revenue	$181.72M	$1.01M	$179.13M
Gross Profit
Net Income / Loss	$153.05M	$-5.14M	$169.7M
Operating Income / Loss	$149M	$-5.96M	$168.91M
Cost of Revenue
Net Cash Flow	$-18.24M	$-4.54M	$5.7M
PE Ratio

Splits
Nov 04, 2010	1:5